. Mean age was 56y, 76% were female. There was no difference in the disease distribution between centers. The most common comorbidities were cardiovascular risk factors and diseases, followed by depression and osteoporosis. The number of comorbidities was significantly associated with age (p<0.001), obesity (p<0.001) and biotherapies (p 0.05). LCA analysis identified 3 main clusters of multimorbidity: OA, RA, AxSPA (Fig 1) . The most optimal screening was found for cardiovascular risk factors (84%). DXA was prescribed in 69% of correct indications. As for malignancies, mammograms and pap smears were the most optimally prescribed (36% and 28%). Colonoscopy and dermatology visit were prescribed in 22% and 18%. Correct vaccination (influenza and pneumococcal) was found in 17% and 8%. Predictive factors for optimal screening were age, university setting, social coverage, disease duration and biotherapy.
Conclusions: Comorbidities are prevalent in RMDs and follow specific multimorbidity patterns, with a predominance for cardiovascular, depression and osteoporosis. They are more frequent with age and obesity. Optimal screening needs to be improved. Background: Gout is a common form of inflammatory arthritis. Treatment guidelines recommend a target serum urate (sUA) ≤6mg/dL. ACR and EULAR treatment guidelines indicate sUA targets may need to be surpassed to achieve treatment benefits in a subset of patient that continue to flare and/or have tophi. Methods: Data were assessed from a survey of physicians about gout disease management. Patient results were confirmed through in-depth chart audits assessing diagnosis, comorbid conditions, disease severity and laboratory assessments. Disease severity was measured using a physician global assessment, flare counts, joint damage and presence of tophi. Type and dose of XOI, length of current treatment, compliance, physician type and patient socio-demographic factors were identified. Descriptive and multivariate statistics were used to describe patients having ≥2 flares per year (excluding treatment-related flares) in patients achieving target sUA ≤6 mg/dL. Results: Overall, 251 rheumatologists and 250 primary care physicians were interviewed and provided data from 2505 patients with gout; 82% were male and the average age was 58 years (SD=12). 1823 (73%) patients were treated with an XOI, of these 813 (44%) had a least one assessment of sUA ≤6 mg/dL over a 12-month period. Of the 813 patients reaching sUA target, 307 (37.8%) reported ≥2 flares in the last year. On average, patients at sUA goal with ≥2 flares had been treated over 38. 
